Pluristyx Inc. Secures Initial Close of Series A Priced Round with Multinational Fortune 500 Company; Round to Remain Open for Syndicate Partners Until September 2nd

Pluristyx announced the Initial Close of their Series A priced round, led by a global Fortune 500 company along with participation from existing investors. The capital will directly accelerate growth, allowing us to rapidly expand our innovative stem cell platform, scale operations and inventory, and continue resolving critical industry bottlenecks for advanced therapies.